0017 GMT - There's no rush to pick up NIB shares even though the stock looks inexpensive, Citi analyst Nigel Pittaway says. He tells clients in a note that he expects the stock to trade at current levels for some time as the market waits for reassurance on the impact of the health insurer's change of CEO. Investors also want evidence that NIB has claims inflation under control, he adds. Citi lowers its target price 1.5% to A$6.45 and keeps a neutral rating on the stock. Shares are down 3.7% at A$5.74. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
November 12, 2024 19:17 ET (00:17 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.